Ann Dermatol.  2011 Sep;23(Suppl 1):S68-S71. 10.5021/ad.2011.23.S1.S68.

Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara(R)) and Debulking Therapy

• Kwon HB
• Choi YS
• Lee JH
• Jin SY
• Kim BJ
• Lee SH
• Lee AY

• KMID: 2156755
• DOI: http://doi.org/10.5021/ad.2011.23.S1.S68

Abstract

Verrucous carcinoma is an unusual, non-metastasizing, distinct variant of squamous cell carcinoma composed of four subtypes according to the site of occurrence: oral type, anogenital type, plantar type, and other cutaneous sites. Oral type verrucous carcinoma usually shows slow progression with a low incidence of metastases. Treatment of verrcous carcinoma is challenging; multiple medical and surgical therapies are often attempted, with limited success. We reported on 2 cases of verrucous carcinoma of the lip treated with topical imiquimod and debulking therapy.

Keyword

Lasers, gas; Cryotherapy; Imiquimod; Carcinoma, verrucous

MeSH Terms

Aminoquinolines
Carcinoma, Squamous Cell
Carcinoma, Verrucous
Cryotherapy
Incidence
Lasers, Gas
Lip
Neoplasm Metastasis
Aminoquinolines

Figure

• 

  Fig. 1 (A) Extensive verrucous, hyperkeraotic tumor on the central aspect of the lower lip. (B) After treatment, all skin lesions disappeared.

• 

  Fig. 2 (A) A biopsy specimen revealed the presence of an endophytic epidermal proliferation with bulbous, blunted projections composed of large, well-differentiated, squamous epithelial cells extending into the reticular dermis (H&E, ×20). (B) Cellular pleomorphism was minimal and mitotic activity was confined to the basal layer (H&E, ×200).

• 

  Fig. 3 (A) Verrucous plaques with fissuring on the right aspect of the lower lip. (B) After treatment, all skin lesions disappeared.

• 

  Fig. 4 A biopsy specimen revealed marked parakeratosis, neoplastic proliferation, and downward invasion of epidermal keratinocytes with a blunt border and a pushed-down, bulldozing appearance (H&E, ×20).

Reference

1. Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery. 1948. 23:670–678.

2. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Glidsmith LA, Katz SI, et al. Fitzpatrick's dermatology in general medicine. 2003. 6th ed. New York: Mcgraw-Hill;742–743.

3. Creasman C, Haas PA, Fox TA Jr, Balazs M. Malignant transformation of anorectal giant condyloma acuminatum (Buschke-Loewenstein tumor). Dis Colon Rectum. 1989. 32:481–487.

4. Kao GF, Graham JH, Helwig EB. Carcinoma cuniculatum (verrucous carcinoma of the skin): a clinicopathologic study of 46 cases with ultrastructural observations. Cancer. 1982. 49:2395–2403.

5. Diaz-Pérez JL, Moreno J, Burgos J. Ackerman's verrucous carcinoma on the lower lip. Med Cutan Ibero Lat Am. 1981. 9:105–110.

6. Krutchkoff DJ, Chen JK, Eisenberg E, Katz RV. Oral cancer: a survey of 566 cases from the University of Connecticut Oral Pathology Biopsy Service, 1975-1986. Oral Surg Oral Med Oral Pathol. 1990. 70:192–198.

7. Zielonka E, Goldschmidt D, de Fontaine S. Verrucous carcinoma or epithelioma cuniculatum plantare. Eur J Surg Oncol. 1997. 23:86–87.

8. Garven TC, Thelmo WL, Victor J, Pertschuk L. Verrucous carcinoma of the leg positive for human papillomavirus DNA 11 and 18: a case report. Hum Pathol. 1991. 22:1170–1173.

9. Knobler RM, Schneider S, Neumann RA, Bodemer W, Radlwimmer B, Aberer E, et al. DNA dot-blot hybridization implicates human papillomavirus type 11-DNA in epithelioma cuniculatum. J Med Virol. 1989. 29:33–37.

10. Stephen JM, Vincent RH. Plastic surgery. 2006. 6th ed. Philadelphia: Elsevier Inc;799–800.

11. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001. 44:807–813.

12. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001. 44:462–470.

13. Kaspari M, Gutzmer R, Kiehl P, Dumke P, Kapp A, Brodersen JP. Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat. Dermatology. 2002. 205:67–69.

14. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000. 43:555–556.

15. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002. 205:135–138.

16. Tyring S. Imiquimod applied topically: a novel immune response modifier. Skin Therapy Lett. 2001. 6:1–4.

17. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg. 2004. 30:1101–1112.

18. Heinzerling LM, Kempf W, Kamarashev J, Hafner J, Nestle FO. Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation. Dermatology. 2003. 207:119–122.

19. Schalock PC, Kornik RI, Baughman RD, Chapman MS. Treatment of verrucous carcinoma with topical imiquimod. J Am Acad Dermatol. 2006. 54:5 Suppl. S233–S235.